Washington University School of Medicine

AstraZeneca PLC and Daiichi Sankyo Co., Ltd. presented data on 8 and 9 September that seem to support their decision to seek US Food and Drug Administration approval for their TROP2-targeting antib

Eisai Co., Ltd. has a challenging task ahead in bringing its Biogen, Inc. -partnered amyloid protofibril-clearing antibody Leqembi (lecanemab) to Alzheimer’s patients in a market that is struggling

After many attempts and failures to bring a disease-modifying therapy forward for Alzheimer’s disease, the triumph of Eisai Co., Ltd. / Biogen, Inc. ’s amyloid protofibril-clearing antibody lecanemab

Approval for Bharat Biotech ’s intranasal COVID-19 vaccine for restricted use in India is a scientific achievement for the company and its partner Washington University School of Medicine in St. Lo